INM InMed Pharmaceuticals Inc.

Nasdaq inmedpharma.com


$ 2.08 $ -0.12 (-5.45 %)    

Thursday, 16-Oct-2025 15:59:50 EDT
QQQ $ 598.23 $ -2.23 (-0.37 %)
DIA $ 458.84 $ -3.15 (-0.68 %)
SPY $ 658.90 $ -4.53 (-0.68 %)
TLT $ 91.49 $ 0.68 (0.75 %)
GLD $ 401.79 $ 9.06 (2.34 %)
$ 2.08
$ 2.22
$ 2.02 x 250
$ 2.24 x 173
$ 2.07 - $ 2.26
$ 1.72 - $ 8.27
74,424
na
nm
$ 2.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 09-22-2025 06-30-2025 10-K
2 05-12-2025 03-31-2025 10-Q
3 02-12-2025 12-31-2024 10-Q
4 11-14-2024 09-30-2024 10-Q
5 09-27-2024 06-30-2024 10-K
6 05-13-2024 03-31-2024 10-Q
7 02-13-2024 12-31-2023 10-Q
8 11-13-2023 09-30-2023 10-Q
9 09-29-2023 06-30-2023 10-K
10 05-15-2023 03-31-2023 10-Q
11 02-17-2023 12-31-2022 10-Q
12 11-14-2022 09-30-2022 10-Q
13 09-23-2022 06-30-2022 10-K
14 05-13-2022 03-31-2022 10-Q
15 02-14-2022 12-31-2021 10-Q
16 11-10-2021 09-30-2021 10-Q
17 09-24-2021 06-30-2021 10-K
18 05-13-2021 03-31-2021 10-Q
19 02-11-2021 12-31-2020 10-Q
20 12-17-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 inmed-pharmaceuticals-will-be-issued-us-patent-number-12357604-tomorrow-titled-topical-formulations-of-cannabinoids-and-use-thereof-in-the-treatment-of-pain

https://x.com/PatentGrants/status/1944848362106462423

 on-june-24-2025-inmed-pharmaceuticals-entered-agreement-to-sell-19m-shares-at-2561-each

-SEC Filing

 why-inmeds-alzheimers-drug-candidate-is-fueling-sudden-stock-surge

InMed stock jumped after preclinical data showed INM-901 lowered brain inflammation tied to Alzheimer's and improved cognit...

Core News & Articles
Market-Moving News for June 24th
06/24/2025 11:16:06

INM: 102% | InMed shares are trading higher after the company announced preclinical data showing INM-901 reduced neuroinflammat...

 inmed-pharmaceuticals-amends-standby-equity-purchase-agreement-with-yorkville-may-from-time-to-time-suspend-use-of-registration-statement-of-shares-under-sepa-with-yorkville

-SEC Filing

 why-inmed-pharmaceuticals-inm-stock-is-skyrocketing

InMed Pharmaceuticals shares are trading higher by 45% during Tuesday's session. The company announced that INM-901 reduced...

 inmed-pharmaceuticals-announces-inm-901-reduced-alzheimers-related-inflammation-achieved-statistically-significant-reduction-in-neurodegeneration-marker-neurofilament-light-chain-and-neuroinflammatory-genes-in-preclinical-study

INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer'sStatistically significant reduction in ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION